Physician profile
Matthew Spellman
NPI 1528695996
$1,280.17
in general payments reported to CMS, 2019-2025
19 companies · $1,280 in 2025
The $1,280 reported for 2025 was more than what 87% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,280.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,280.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,280.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $213.00 | 2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $155.86 | 2025 | |
| Lilly USA, LLC | $129.24 | 2025 | Jardiance, Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $98.65 | 2025 | Breztri, Airsupra, Farxiga |
| Axsome Therapeutics, INC. | $97.22 | 2025 | Auvelity |
| Astellas Pharma US INC | $95.67 | 2025 | Veozah |
| Phathom Pharmaceuticals, INC. | $85.66 | 2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $70.67 | 2025 | |
| Amgen INC. | $62.99 | 2025 | Evenity, Otezla, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $57.17 | 2025 | Jardiance |
| Glaxosmithkline, LLC. | $35.16 | 2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Viatris Specialty LLC | $32.87 | 2025 | Yupelri |
| Otsuka America Pharmaceutical, INC. | $27.00 | 2025 | Voyxact |
| Vertex Pharmaceuticals Incorporated | $25.87 | 2025 | |
| Verona Pharma, INC. | $23.73 | 2025 | Ohtuvayre |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $21.69 | 2025 | The Cologuard Plus Collection Kit |
| Merck Sharp & Dohme LLC | $17.06 | 2025 | Lagevrio |
| Esperion Therapeutics, INC. | $17.05 | 2025 | Nexletol |
| Pfizer INC. | $13.61 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Spellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.